EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi iD, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo iD

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Lei Jin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fuda…. Hauptthemen laut MEDLINE: Myasthenia Gravis, Adaptive Immunity, Immunity, Innate, Receptors, Fc. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.

Methods

We first quantified FcRn expression in peripheral immune subsets from acetylcholine receptor antibodies (AChR‐Ab) positive gMG. Then we assessed efgartigimod's impact on immune cells via in‐depth profiling in vitro and later validated these findings in a prospective real‐world cohort treated with efgartigimod.

Results

High FcRn expression was abundantly expressed on monocytes and lymphocytes in an exploratory MG cohort ( n = 29), with notable intracellular presence. In vitro studies showed efgartigimod significantly decreased intracellular FcRn in monocytes ( p < 0.001) and lymphocytes ( p = 0.019). After efgartigimod treatment, non‐classical monocytes (CD14 low CD16 + , 17.89 ± 9.60 vs. 14.58 ± 9.89 cells/μl, p < 0.001; 3.20 ± 2.06 vs. 2.61% ± 2.12%, p < 0.001) and Th17.1 cells (CXCR3 + CCR6 + , 95.83 ± 66.56 vs. 84.06 ± 61.70 cells/μl, p = 0.010; 10.42 ± 4.82 vs. 9.06% ± 4.46%, p = 0.000) were significantly downregulated. In contrast, antibody‐producing B cells and effector‐memory CD4 + and CD8 + T cells were expanded. Longitudinal assessments in the gMG cohort displayed similar findings, which likely reflect the direct inhibitory effect of efgartigimod on monocytes, coupled with negative feedback due to decreased IgG levels.

Conclusions

By integrating in vitro and clinical findings, we demonstrate that efgartigimod modulates peripheral immune cell populations, highlighting its significant immunomodulatory effects and clinical potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisAdaptive ImmunityImmunity, InnateReceptors, FcMonocytesLymphocytesHumansMaleFemaleMiddle AgedAdultAgedHistocompatibility Antigens Class I

Stichwörter der Autor:innen

EfgartigimodFcRngeneralized myasthenia gravisin‐depthperipheral immune cells

Substanzen

Fc receptor, neonatalReceptors, FcHistocompatibility Antigens Class I

Autor:innen und Institutionen

  • Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai, China.
  • Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Jianying Xi, Sushan Luo

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Jin, L., Dong, L., Wang, Y., He, D., Yan, C., Xi, J., Jiang, H., Shi, Y., Guan, M., Zhao, C., Song, J., & Luo, S. (2026). In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70283

Vancouver

Jin L, Dong L, Wang Y, He D, Yan C, Xi J, et al. In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70283

BibTeX
@article{Jin2026,
  author = {Jin, Lei and Dong, Liu and Wang, Ying and He, Dingxian and Yan, Chong and Xi, Jianying and Jiang, Haoqin and Shi, Yu and Guan, Ming and Zhao, Chongbo and Song, Jie and Luo, Sushan},
  title = {In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70283}
}
Kostenlos starten →